Dynavax Technologies Corp. (NASDAQ:DVAX) shares saw strong trading volume on Thursday . 1,119,899 shares were traded during trading, an increase of 74% from the previous session’s volume of 643,472 shares.The stock last traded at $16.07 and had previously closed at $15.72.

Several analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a research report on Monday, June 27th. Cowen and Company reiterated a “buy” rating and set a $60.00 price target on shares of Dynavax Technologies Corp. in a research report on Thursday, April 28th. Royal Bank Of Canada lowered shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and reduced their price target for the stock from $48.00 to $17.00 in a research report on Wednesday, April 27th. Finally, JPMorgan Chase & Co. lowered shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $29.00 to $22.00 in a research report on Wednesday, April 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Dynavax Technologies Corp. has an average rating of “Hold” and a consensus target price of $32.20.

The company’s market capitalization is $614.03 million. The company’s 50-day moving average is $15.12 and its 200 day moving average is $17.34.

Dynavax Technologies Corp. (NASDAQ:DVAX) last announced its quarterly earnings data on Friday, August 5th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.07. The business had revenue of $2.65 million for the quarter, compared to analyst estimates of $1.58 million. During the same quarter last year, the company posted ($0.80) earnings per share. The business’s revenue for the quarter was up 70.8% on a year-over-year basis. On average, analysts expect that Dynavax Technologies Corp. will post ($2.96) earnings per share for the current year.

In other Dynavax Technologies Corp. news, CEO Eddie Gray purchased 2,750 shares of the stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $15.57 per share, with a total value of $42,817.50. Following the completion of the transaction, the chief executive officer now directly owns 5,050 shares in the company, valued at approximately $78,628.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

An institutional investor recently raised its position in Dynavax Technologies Corp. stock. Trexquant Investment LP raised its stake in shares of Dynavax Technologies Corp. (NASDAQ:DVAX) by 14.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,200 shares of the biopharmaceutical company’s stock after buying an additional 8,911 shares during the period. Trexquant Investment LP owned about 0.18% of Dynavax Technologies Corp. worth $1,696,000 as of its most recent SEC filing.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.